...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Drugs of today: Medicamentos de actualidad >Nanoparticle albumin-bound paclitaxel for treatment of metastatic breast cancer.
【24h】

Nanoparticle albumin-bound paclitaxel for treatment of metastatic breast cancer.

机译：纳米颗粒白蛋白结合紫杉醇治疗转移性乳腺癌。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Two taxanes, paclitaxel and docetaxel, are among the most widely used chemotherapeutic agents in solid tumor oncology, with efficacy against tumors of the breast, lung, head and neck, ovary, prostate, stomach and urothelium. The taxanes have been studied extensively and have been proven effective for treating early and advanced breast cancer. However, paclitaxel and docetaxel are both highly hydrophobic compounds, requiring synthetic solvents for parenteral administration. The solvents in commercially available preparations cause life-threatening toxic effects and decreased efficacy, and they are inconvenient to administer. Nanoparticle albumin-bound paclitaxel (nabP) is a novel, solvent-free formulation of paclitaxel. With nabP, in contrast to standard paclitaxel, life-threatening hypersensitivity reactions have not been observed, and it can be administered safely without steroid and antihistamine premedication. Furthermore, nabP exploits cellular and tumor transport mechanisms to preferentially target tumor cells. Data from phase III studies of metastatic breast cancer demonstrated higher response rates, longer time to progression and an improved toxicity profile for nabP compared with standard paclitaxel. The U.S. Food and Drug Administration approved nabP in late 2004 for treatment of metastatic breast cancer after failure of an anthracycline-based regimen.
机译：紫杉醇和紫杉醇这两种紫杉烷类化合物是实体瘤肿瘤学中使用最广泛的化学治疗剂，对乳腺癌，肺癌，头颈癌，卵巢癌，前列腺癌，胃癌和尿路上皮肿瘤都有疗效。紫杉烷类已被广泛研究，并已被证明可有效治疗早期和晚期乳腺癌。然而，紫杉醇和多西紫杉醇都是高度疏水的化合物，需要非肠道给药的合成溶剂。市售制剂中的溶剂导致危及生命的毒性作用和降低的功效，并且不方便施用。纳米粒子结合白蛋白的紫杉醇（nabP）是一种新型的无溶剂的紫杉醇制剂。与标准紫杉醇相比，使用nabP尚未观察到危及生命的超敏反应，并且无需类固醇和抗组胺药就可安全给药。此外，nabP利用细胞和肿瘤转运机制优先靶向肿瘤细胞。与标准紫杉醇相比，来自转移性乳腺癌的III期研究的数据表明，nabP的应答率更高，进展时间更长且毒性改善。美国食品药品监督管理局（FDA）在2004年底批准了nabP治疗基于蒽环类的治疗方案失败后的转移性乳腺癌。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号